Views & Analysis | Perspectives on pharma industry issues

R&D

Tauklarify PET approval for Lantheus in AD NFT pathology

The FDA approves Lantheus' Tauklarify radiodiagnostic PET to evaluate NFT pathology in Alzheimer's disease.

R&D

Why storage resilience will protect the future of CAR-T

Cell and gene therapies are changing the way pharmaceutical organisations think about sample storage.

Patients

Reshaping the future of patient-centric drug development

Strategic partnerships, robust quality systems, and manufacturing know-how will support next-generation therapies with patient-centric designs.

R&D

Changing Faces: Pharma and biotech hires, June & July 2026

In June/July, companies continued to reshape their leadership teams in preparation for upcoming clinical, regulatory, and commercial milestones.

Sales & Marketing

Sponsored

Personalisation is the biggest lie brands keep telling

Pharma brands need to move beyond surface-level personalisation and focus on measurable impact.

Patients

The unexpected starting line: Solving drug affordability at ...

In early 2025, the White House renewed its push to lower prescription drug prices, part of an executive order aimed at easing patients' financial burdens.

R&D

pharmaceutical workforce - a lab with one human worker

When costing and compliance collide

Only a few years ago, compliance was the undisputed top priority in the pharmaceutical industry - regardless of cost.

Digital

Boosting trust in AI: The essential foundation for breakthro...

The use of artificial intelligence (AI) in healthcare is growing rapidly and already providing patients with better care and support.

Sales & Marketing

Sponsored

Personalisation is the biggest lie brands keep telling

Pharma brands need to move beyond surface-level personalisation and focus on measurable impact.

Sales & Marketing

M&A trends in diagnostics and life sciences tools

The diagnostics and life sciences tools sector is attracting continued investor interest across both private equity and large corporates.

Digital

Australia, AI, and Autolomous

pharmaphorum spoke with Alexander Seyf, CEO of Autolomous, about the future of AI in Australian biotech.

Digital

Nurse affixes a smart device to an elderly patient's wrist

Smaller, smarter devices for global trial diversity

Consumer device giants are surging into the healthcare arena to make devices cheaper, more compact, and easier for patients to use.

Market Access

Europe’s new HTA reality: The JCA, one year on

Here, we examine the early realities of JCA implementation, exploring whether the system is delivering greater alignment across European markets.

Market Access

Three separate injections - blue, red, and yellow - take off against black background

Why global pharmaceutical reforms are quietly redirecting ra...

Publication of the 2026 Pharma Package by the Council of the EU represents the most significant reform of EU pharmaceutical legislation in over 20 yrs